Eaton Boosts 2024 Guidance As Electrical And Aerospace Sectors Excel

Eaton reports strong Q1 FY24 results with record sales of $5.94B, 8% Y/Y growth, and increased backlog. Q2 outlook exceeds expectations and FY24 guidance raised.

Eaton Corporation plc (NYSE:ETN) on Tuesday reported a first-quarter FY24 net sales growth of 8% Y/Y to $5.94 billion, beating the consensus of $5.91 billion.

Organic growth of 8% Y/Y was at the high end of guidance in the quarter.

Sales by segments: Electrical Americas $2.7 billion (+17% Y/Y), Electrical Global $1.5 billion (flat Y/Y), Aerospace $871 million (+9% Y/Y), Vehicle $724 million (-2% Y/Y) and eMobility $158 million (+7% Y/Y).

Eaton reported strong growth in the Electrical sector backlog, up 27% with a book-to-bill ratio of 1.2, and the Aerospace backlog, up 11% with a book-to-bill ratio of 1.1.

Total segment operating profit margin expanded by 340 bps Y/Y to 23.1%.

Eaton’s operating cash flow in the quarter was $475 million, up 42% Y/Y, and free cash flow was $292 million (+40% Y/Y).

Adjusted EPS improved 28% Y/Y to $2.40, beating the consensus of $2.29.

Craig Arnold, Eaton chairman and chief executive officer said,  “Growth drivers like increased project activity tied to megatrends, reindustrialization and infrastructure spending continue to drive demand for Eaton’s solutions across our markets, and we remain very confident in our teams’ ability to execute on our increased targets for the year.” 

“We capitalized on strong growth in our business to start the year, resulting in strong order growth in Electrical and Aerospace and first quarter record segment margins.”

Related: Eaton Is Poised To Benefit From ‘Ongoing Electrical Super-Cycle,’ Says Bullish Analyst

Q2 FY24 Outlook: The company expected Adjusted EPS of $2.52-$2.62 versus $2.50 consensus, organic revenue growth of 6.5%-8.5%, and segment operating margins of 22.4%-22.8%.

FY24 Guidance, raised: Eaton increased adjusted EPS to $10.20-$10.60 (from $9.95-$10.35 prior) vs. $10.25 estimate, organic revenue growth to 7%-9% (from 6.5%-8.5%) and segment operating margins to 22.8%-23.2% (from 22.4%-22.8%).

Investors can gain exposure to the stock via First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund (NASDAQ:GRID) and Neuberger Berman ETF Trust Neuberger Berman Carbon Transition Infrastructure ETF (NYSE:NBCT).

Price Action: ETN shares are down 1.4% at $321.93 at last check Tuesday.

Now Read: Goldman Sachs Tempers Investor Excitement On Tesla Self-Driving Tech In China: ‘Not Yet An Eyes-Off, Unsupervised Product’

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Ideal Power Reports Q1 Earnings, CEO Expects Solid-State Circuit Breaker Market To Grow Revenue

Ideal Power Inc (NASDAQ:IPWR) reported first-quarter FY24 commercial revenue of $78,739, a notable increase from zero last year. Operating expenses fell to $2.5 million from $2.6 million. The company completed a public offering, raising $15.7 million, and held $20.2 million in cash by March 31, 2024, with no outstanding long-term debt. Ideal Power expects its SymCool power module to drive early sales in industrial markets.

IPWR

Read More

Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say ‘There’s No Stepping Back’ From Legalization Wave

Flora Growth Corp. has entered into a definitive agreement to acquire all of the issued and outstanding shares of Hamburg, Germany-based TruHC Pharma GmbH. The company's latest move to further cement its global footprint comes on the heels of a new German cannabis law that went into effect on April 1, which partially legalized cannabis. The new law allows adults over 18 in Germany to legally possess up to 25 grams of dried cannabis and cultivate up to three marijuana plants at home.As previously announced, Flora agreed to purchase TruHC Pharma GmbH in an all-stock deal in exchange for 2,770,562 of its common shares, valued at $6.4 million.

ACB

Read More

Scorpion Capital Tweets “Minutes ago, the FDA replied to our Citizen Petition requesting withdrawal of approval of Harmony Biosciences’ drug Wakix. We are pleased that the FDA Is taking our concerns seriously, view the interim response as ominous for C…

https://twitter.com/ScorpionFund/status/1704944718411362498https://scorpionreports.s3.us-east-2.amazonaws.com/FDA-2023-P-1273.pdfMinutes ago, the FDA replied to our Citizen Petition requesting withdrawal of approval of

HRMY